Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2019 Dec 1.

Published in final edited form as: Sleep Med. 2018 Sep 20;52:168–176. doi: 10.1016/j.sleep.2018.09.001

Table 3.

Cox proportional hazards—main effects for e4 carrier status. Outcome: MCI.

Predictor Variables	Analytic sample size	_E4 Carrier	_E4 Carrier	_E4 Carrier
		Main Effects (Unadjusted)	Main Effects Adjusted^a	Main Effects Adjusted^b w/AD Medication use

		Hazard Ratio (95% CI)	Hazard Ratio (95% CI)	Hazard Ratio (95% CI)

Whole Analytic Sample	6798	1.30(1.14-1.50)^***	1.62 (1.41–1.87)^***	1.60(1.39–1.84)^***
Use of sleep medication	732	1.21 (0.81–1.80)	1.52 (1.02–2.28)^**	1.44 (0.95–2.16)
Did not use sleep medication	6066	1.32 (1.14-1.52)^***	1.64 (1.41–1.91)^***	1.63 (1.40–1.90)^***
- Trazodone Use	268	1.17 (0.59-2.34)	1.56 (0.77–3.15)	1.62 (0.76–3.48)
- No Trazodone Use	6530	1.31 (1.14-1.51)^***	1.63 (1.41–1.89)^***	1.62 (1.40–1.87^***
- Zolpidem use	439	1.13 (0.68-1.88)	1.46 (0.86–2.50)	1.30 (0.76–2.22)
- No Zolpidem use	6359	1.32 (1.14-1.52)^***	1.63 (1.41–1.89)^***	1.62 (1.39–1.88)^***

^***

p < 0.01,

^**

p < 0.05,

^*

p < 0.1.

^a

Adjusted for sex, age, education, race, and Hispanic origin.

^b

Adjusted for sex, age, education, race, Hispanic origin, and AD medication use.